Table 51-20.

Studies of Preemptive Barrier Isolation to Contain Spread of Multiresistant Organisms

	Control of Epidemic Spread		Control of Endemic Infections
			Before-After and Nonrandomized Trials		Randomized Trials
Preemptive Barrier Isolation Precautions for All High-Risk Patients	No. of Outbreaks	No. (%) Totally Controlled	Author	RR (95% CI)	Author	RR (95% CI)
Methicillin-resistant Staphylococcus aureus	2525	2 (100)525	Safdar532	0.36 (0.13-0.98)*	No studies
Vancomycin-resistant Enterococcus	2525, 526	2 (100)525, 526	Montecalvo534	0.22 (0.05-0.92)*	No studies
			Slaughter531	2.66 (1.00-6.77)†
			Morris535	1.18 (NR)†
			Srinivasan533	0.47 (NR)*
			All studies	0.22-2.66
Resistant gramnegative bacilli	none		McManus614	0.38 (0.31-0.46)*	No studies
Clostridium difficile	none		Johnson241	0.19 (NR)*	No studies
Other
Necrotizing enterocolitis			Agbayani522	0.13 (0.02-0.84)*
Respiratory syncytial virus			Leclair78	0.34 (0.17-0.60)*
All nosocomial infections			Slaughter531	1.51 (0.74-3.12)†	Slota528	0.48 (NR)*
					Klein527	0.19 (0.05-0.70)*
					Koss530	1.86 (1.10-3.16)*

^*P < 0.05

^†P > 0.05